7月23日，Elevance Health盘前上涨3.06%，报390.82美元/股，成交额4.34万美元。公司延续Q2财报发布后的超跌修复走势。
消息面上，公司Q2调整后EPS为7.45美元，大幅超出市场预期的6.21美元，全年指引上调至至少27美元。财报发布当日因医疗补助业务利用率压力及营业利润率下滑，股价一度重挫逾10%。此后多家投行密集上调目标价：Wells Fargo上调至492美元、Truist上调至475美元、Guggenheim上调至455美元。当前FactSet汇总均值目标价为445.57美元，较现价仍有显著上行空间。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.